Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. https://doi.org/10.1182/blood.2022015850.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. https://doi.org/10.1038/s41375-022-01613-1.

Article  PubMed  PubMed Central  Google Scholar 

Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. a multicenter study of 507 patients. Am J Hematol. 2017;92:37–41. https://doi.org/10.1002/ajh.24572.

Article  CAS  PubMed  Google Scholar 

Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801–21. https://doi.org/10.1002/ajh.26857.

Article  CAS  PubMed  Google Scholar 

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29:2126–33. https://doi.org/10.1038/leu.2015.233.

Article  CAS  PubMed  Google Scholar 

Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M. et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11:e62–74. https://doi.org/10.1016/S2352-3026(23)00305-8.

Article  PubMed  Google Scholar 

Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954–2954.

Article  CAS  PubMed  Google Scholar 

Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol. 1990;75:4–9.

Article  CAS  PubMed  Google Scholar 

Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:69–79.

Article  CAS  PubMed  Google Scholar 

Luther M, Henes FO, Zabelina T, Massoud R, Janson D, Wolschke C, et al. Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2023;58:755–61.

Article  CAS  PubMed  Google Scholar 

Passamonti F, Mora B. Myelofibrosis. Blood 2023;141:1954–70.

Article  CAS  PubMed  Google Scholar 

Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D’Adda M, Deeg HJ, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10:e59–70.

Article  CAS  PubMed  Google Scholar 

Tremblay D, Schwartz M, Bakst R, Patel R, Schiano T, Kremyanskaya M, et al. Modern management of splenomegaly in patients with myelofibrosis. Ann Hematol. 2020;99:1441–51.

Article  PubMed  PubMed Central  Google Scholar 

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–98.

Article  CAS  PubMed  Google Scholar 

Pardanani A, Tefferi A. How I treat myelofibrosis after failure of JAK inhibitors. Blood. 2018;132:492–500. https://doi.org/10.1182/blood-2018-02-785923.

Article  CAS  PubMed  Google Scholar 

Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia 2021;35:3551–60.

Article  PubMed  PubMed Central  Google Scholar 

Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. JAMA Oncol. 2018;4:652.

Article  PubMed  PubMed Central  Google Scholar 

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317–24.

Article  PubMed  PubMed Central  Google Scholar 

Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023;10:e735–46.

Article  CAS  PubMed  Google Scholar 

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401:269–80. https://doi.org/10.1016/S0140-6736(22)02036-0.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis. Am J Hematol. 2024;99:844–53.

Article  CAS  PubMed  Google Scholar 

Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, et al. Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024;59:550–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kitanaka A, Takenaka K, Shide K, Miyamoto T, Kondo T, Ozawa K, et al. Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. Int J Hematol. 2016;103:423–8.

Article  CAS  PubMed  Google Scholar 

Kalman NS, Mukhopadhyay ND, Roberts CH, Chung HM, Clark WB, McCarty JM, et al. Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis. Leuk Lymphoma. 2017;58:2983–4.

Article  PubMed  Google Scholar 

Bales JR, Kim HT, Portillo R, Patel C, McAfee S, Dey B, et al. Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Bone Marrow Transplant. 2023;58:459–61.

Article  PubMed  Google Scholar 

Campodonico E, Xue E, Piemontese S, Chiara A, Bruno A, Scorpio G, et al. Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: a pilot experience. Curr Res Transl Med. 2023;71:103400.

CAS  PubMed  Google Scholar 

Finazzi MC, Tefferi A, Rambaldi A. JAK inhibitor treatment‐resistant splenomegaly before transplantation in myelofibrosis: splenectomy or radiotherapy? Am J Hematol. 2024;99:804–5.

Article  CAS  PubMed  Google Scholar 

Ferreira Gomes G, Harrison C. Pelabresib (CPI-0610): an exciting novel drug for the treatment of myelofibrosis. Curr Hematol Malig Rep. 2023;18:113–20.

Article